Cendifensine (INNTooltip International Nonproprietary Name) is a monoamine reuptake inhibitor (MRI)[1] related to the amphetamines and cathinones which has not been marketed at this time.[2][3][4] It was first described by 2013[4] and its INNTooltip International Nonproprietary Name was proposed in 2024.[2] The drug has been patented by Noema Pharma, which is developing a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) known as NOE-115 for the treatment of vasomotor symptoms as well as for binge-eating disorder and depressive disorders.[5][6][7]

See also

References

  1. ^ WO 2023/161533A1, Garibaldi G, "Triple uptake inhibitor for the treatment of atypical depression", published 31 August 2023, assigned to Noema Pharma AG 
  2. ^ a b "Proposed INN: List 132 International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 38 (4). 2024. cendifensinum cendifensine (3,4-dichlorophenyl)[(3S)-3-propylpyrrolidin-3-yl]methanone monoamine reuptake inhibitor [...] C14H17Cl2NO 1034048-49-1
  3. ^ "(3,4-Dichlorophenyl)[(3S)-3-propyl-3-pyrrolidinyl]methanone". Global Substance Registration System (GSRS). National Center for Advancing Translational Sciences (NCATS), U.S. National Institutes of Health. Retrieved 24 February 2025.
  4. ^ a b CA 2860810A1, Adam JM, Dvorak CA, Fishlock D, Humphreys ER, Iding H, Pfleger C, Rege PD, Shi X, Vitale J, Wang S, Zajac M, "(3,4-dichloro-phenyl)-((s)-3-propyl-pyrrolidin-3-yl)-methanone hydrochloride and manufacturing processes", published 23 April 2013, assigned to F Hoffmann La Roche AG 
  5. ^ "NOE 115". AdisInsight. 21 May 2024. Retrieved 24 February 2025.
  6. ^ "Delving into the Latest Updates on Noema Pharma AG with Synapse". Synapse. 23 January 2025. Retrieved 24 February 2025.
  7. ^ "Noema Pharma". Noema Pharma. 18 June 2021. Retrieved 24 February 2025.
Allikas: https://en.wikipedia.org/wiki/Cendifensine
No tags for this post.